Details of the Drug Combinations

General Information of This Drug (ID: DMADCYE)

Drug Name

Thymalfasin DMADCYE

Synonyms

Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis virus infection	1E50-1E51	Approved	[1]
Liver cancer	2C12	Phase 2	[2]
Melanoma	2C30	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cisplatin + Thymalfasin	DCJ3HN3	Cisplatin	Hepatitis virus infection	[3]
Lamivudine + Thymalfasin	DC5MBBH	Lamivudine	Hepatitis B virus infection	[4]
Thymalfasin + Mycophenolate mofetil	DCLF0JG	Mycophenolate mofetil	IrAE	[5]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	ClinicalTrials.gov (NCT01031966) A Pilot Study to Evaluate ZADAXIN's (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of SciClone Pharmaceuticals.
4	Clinical pipeline report, company report or official report of SciClone.
5	ClinicalTrials.gov (NCT06178146) Thymosin Alpha-1 for irAE Secondary to ICIs